Literature DB >> 15069806

Five-year relative survival from prostate, breast, colorectal and lung cancer.

L F Ellison1, L Gibbons.   

Abstract

OBJECTIVES: This article presents five-year relative survival rates for prostate, breast, colorectal and lung cancer diagnosed in 1992. Provincial variations are also examined. DATA SOURCES: Data are from the Canadian Cancer Registry, the National Cancer Incidence Reporting System, the Canadian Mortality Data Base, and life tables. ANALYTICAL TECHNIQUES: Analysis was conducted using the maximum likelihood method of Estève. Provincial rates were standardized to the age distribution of patients diagnosed with the specific cancer. Statistical tests were conducted to determine if the site-specific age-standardized provincial relative survival rates should be regarded as heterogeneous. (National estimates exclude Québec.) MAIN
RESULTS: Five-year relative survival rates for ages 15 to 99 were highest for prostate cancer (88%) and lowest for lung cancer (17%, women; 14%, men). Relative survival rates for prostate, breast and male lung cancer differ among provinces. There was little inter-provincial variation in relative survival rates for colorectal cancer.

Entities:  

Mesh:

Year:  2001        PMID: 15069806

Source DB:  PubMed          Journal:  Health Rep        ISSN: 0840-6529            Impact factor:   4.796


  7 in total

1.  The changing age distribution of prostate cancer in Canada.

Authors:  C Ineke Neutel; Ru-Nie Gao; Paul A Blood; Leslie A Gaudette
Journal:  Can J Public Health       Date:  2007 Jan-Feb

2.  Ten-year follow-up of a province-wide cohort of surgical lung cancer patients in Nova Scotia.

Authors:  Daniel R Wong; Harry J Henteleff
Journal:  Can J Surg       Date:  2008-08       Impact factor: 2.089

3.  Cancer incidence and survival among Métis adults in Canada: results from the Canadian census follow-up cohort (1992-2009).

Authors:  Maegan V Mazereeuw; Diana R Withrow; E Diane Nishri; Michael Tjepkema; Eduardo Vides; Loraine D Marrett
Journal:  CMAJ       Date:  2018-03-19       Impact factor: 8.262

4.  Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.

Authors:  Wei Cao; Ying Liu; Ran Zhang; Bo Zhang; Teng Wang; Xianbing Zhu; Lin Mei; Hongbo Chen; Hongling Zhang; Pinghong Ming; Laiqiang Huang
Journal:  Sci Rep       Date:  2015-07-13       Impact factor: 4.379

5.  Differences in cancer survival by area-level socio-economic disadvantage: A population-based study using cancer registry data.

Authors:  Nina Afshar; Dallas R English; Tony Blakely; Vicky Thursfield; Helen Farrugia; Graham G Giles; Roger L Milne
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  SMC1A knockdown induces growth suppression of human lung adenocarcinoma cells through G1/S cell cycle phase arrest and apoptosis pathways in vitro.

Authors:  Yi-Fan Zhang; Rui Jiang; Jin-Dong Li; Xing-Yi Zhang; Peng Zhao; Miao He; Hou-Zhong Zhang; Li-Ping Sun; Dong-Lei Shi; Guang-Xin Zhang; Mei Sun
Journal:  Oncol Lett       Date:  2013-01-08       Impact factor: 2.967

7.  Breast Cancer in Canadian Women.

Authors:  Heather Bryant
Journal:  BMC Womens Health       Date:  2004-08-25       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.